US23283X2062 - Common Stock
CYTOSORBENTS CORP
NASDAQ:CTSO (5/2/2024, 7:00:00 PM)
After market: 0.8192 0 (-0.02%)0.8194
-0.02 (-2.53%)
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 198 full-time employees. The company went IPO on 2005-06-17. Its lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR, ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
CYTOSORBENTS CORP
305 College Road East
Princeton NEW JERSEY 08852
P: 19733298885
CEO: Phillip P. Chan
Employees: 198
Website: https://cytosorbents.com/
CytoSorbents to Report First Quarter 2024 Operating and Financial Results...
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CytoSorbents (NASDAQ:CTSO) just reported results for the fourth quarter of 2023...
Here you can normally see the latest stock twits on CTSO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: